within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG12_Ofatumumab;

model Ofatumumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AG12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AG12</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ofatumumab is a fully human monoclonal antibody that specifically binds to the CD20 molecule present on the surface of B lymphocytes. It is used primarily for the treatment of chronic lymphocytic leukemia (CLL) and relapsing forms of multiple sclerosis (MS). Ofatumumab is approved and currently in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adult patients with relapsing multiple sclerosis receiving subcutaneous ofatumumab.</p><h4>References</h4><ol><li><p>Bar-Or, A, et al., &amp; Fox, EJ (2022). Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> 28(6) 910–924. DOI:<a href=&quot;https://doi.org/10.1177/13524585211044479&quot;>10.1177/13524585211044479</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34605319/&quot;>https://pubmed.ncbi.nlm.nih.gov/34605319</a></p></li><li><p>Yu, H, et al., &amp; Soelberg Sørensen, P (2022). Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. <i>CNS drugs</i> 36(3) 283–300. DOI:<a href=&quot;https://doi.org/10.1007/s40263-021-00895-w&quot;>10.1007/s40263-021-00895-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35233753/&quot;>https://pubmed.ncbi.nlm.nih.gov/35233753</a></p></li><li><p>Kurrasch, R, et al., &amp; Chang, DJ (2013). Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. <i>The Journal of rheumatology</i> 40(7) 1089–1096. DOI:<a href=&quot;https://doi.org/10.3899/jrheum.121118&quot;>10.3899/jrheum.121118</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23729801/&quot;>https://pubmed.ncbi.nlm.nih.gov/23729801</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ofatumumab;
